Seres Therapeutics Priced, Nasdaq: MCRB

Developing therapies that replace beneficial colon bacteria to treat infections.

Industry: Health Care

Latest Trade: $13.74 0.00 (0.0%)

First Day Return: +185.6%

Return from IPO: -23.7%

Industry: Health Care

We are a microbiome therapeutics platform company developing a novel class of biological drugs, which are designed to treat disease by restoring the function of a dysbiotic microbiome. Our lead product candidate, SER-109, is designed to prevent further recurrences of Clostridium difficile infection, or CDI, a debilitating infection of the colon, by treating the dysbiosis of the colonic microbiome and, if approved by the FDA, could be a first-in-field drug. Using our microbiome therapeutics platform, we are developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease, including ulcerative colitis and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. We are also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; other inflammatory diseases, such as Crohn’s disease; and infections related to antibiotic use, cancer chemotherapy and immune suppression.
more less
IPO News for Seres Therapeutics
more
IPO Data
IPO File Date 05/27/2015
Offer Price $18.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.4
Deal Size ($mm) $134
IPO Data
IPO Date 06/25/2015
Offer Price $18.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.4
Deal Size ($mm) $134
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2010
Employees 46
Website www.serestherapeutics.com